Download MendeleyDihydroxyphenylisoindoline amides as orally bioavailable inhibitors of the heat shock protein 90 (hsp90) molecular chaperone.
Kung, P.P., Huang, B., Zhang, G., Zhou, J.Z., Wang, J., Digits, J.A., Skaptason, J., Yamazaki, S., Neul, D., Zientek, M., Elleraas, J., Mehta, P., Yin, M.J., Hickey, M.J., Gajiwala, K.S., Rodgers, C., Davies, J.F., Gehring, M.R.(2010) J Med Chem 53: 499-503
- PubMed: 19908836
- DOI: https://doi.org/10.1021/jm901209q
- Primary Citation of Related Structures:
3K97, 3K98, 3K99 - PubMed Abstract:
The discovery and optimization of potency and metabolic stability of a novel class of dihyroxyphenylisoindoline amides as Hsp90 inhibitors are presented. Optimization of a screening hit using structure-based design and modification of log D and chemical structural features led to the identification of a class of orally bioavailable non-quinone-containing Hsp90 inhibitors. This class is exemplified by 14 and 15, which possess improved cell potency and pharmacokinetic profiles compared with the original screening hit.
Organizational Affiliation:
Pfizer Global Research and Development, La Jolla Laboratories, 10770 Science Center Drive, San Diego, California 92121, USA. peipei.kung@pfizer.com
